The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
Amid scrutiny over Robert F. Kennedy Jr.'s pledge to divest his financial stake in vaccine lawsuits to his family, legal ...
Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...
11hon MSN
MRK provided 2025 adjusted EPS guidance of $8.88 to $9.03, while the giant drugmaker expects sales of $64.1 billion to $65.6 ...
This update provides insights into critical global health developments, including Merck's halt on Gardasil shipments to China ...
The drug company’s outlook for 2025 and a slide in sales of its HPV vaccine, Gardasil, hit shares.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback